drugset
Drugs / ECC5004
last change 5 days ago re-read 3 minutes ago

ECC5004

also known as AZD5004

Small molecule targets GLP1R via activation

Developed for
type 2 diabetes mellitus
Investigated by
Eccogene

Trials 3

today NCT06293742 · Ph 1 NCT06268145 · Ph 1 NCT05654831 · Ph 1
2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT06293742 Feb → Apr 2024 type 2 diabetes mellitus Eccogene Completed No outcome recorded
Phase 1 NCT06268145 Feb → Mar 2024 type 2 diabetes mellitus Eccogene Completed No outcome recorded
Phase 1 NCT05654831 Dec 2022 → Nov 2023 type 2 diabetes mellitus Eccogene Completed No outcome recorded

Press releases naming this drug 7 releases

DateIssuerRelease
2026-09-28 Eccogene Eccogene Receives $50 Million Milestone Payment from AstraZeneca Following Initiation of Global Phase 3 Program for Elecoglipron (AZD5004/ECC5004) eccogene.com ↗
2026-06-01 Eccogene Multiple Clinical Trial Data for Elecoglipron (AZD5004/ECC5004), an Oral GLP-1 Receptor Agonist, to be Presented at ADA 2026 eccogene.com ↗
2026-02-10 Eccogene Eccogene Announces Positive Topline Results from Phase 1b Trial of Elecoglipron (AZD5004/ECC5004), an Oral GLP-1 Receptor Agonist, in Adult Participants Living with Obesity/Overweight, with or without Type 2 Diabetes in China eccogene.com ↗
2025-06-18 Eccogene Eccogene Announces First Patient Dosed in Phase 1b Trial of AZD5004/ECC5004, a Novel Oral GLP-1 Receptor Agonist, in China eccogene.com ↗
2024-10-23 Eccogene Eccogene Receives Milestone Payment of $60 Million from AstraZeneca Following Dosing of the First Patient in Global Phase 2b Program of ECC5004/AZD5004 for the Treatment of Obesity and Type 2 Diabetes eccogene.com ↗
2023-11-09 Eccogene Eccogene Enters Exclusive License Agreement With AstraZeneca to Develop and Commercialize Small Molecule GLP-1 Receptor Agonist ECC5004 for Cardiometabolic Diseases eccogene.com ↗
2022-11-03 Eccogene Eccogene Announces US IND Approval for GLP-1 Receptor Agonist ECC5004 eccogene.com ↗

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as ECC5004 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06293742 ↗
2

NCT05654831 ↗

NCT06268145 ↗
Known as AZD5004 “Non-clinical and first-in-human characterization of ECC5004/AZD5004, a novel once-daily, oral small-molecule GLP-1 receptor agonist.” PMID 39495140 ↗ Nov 2024
Action Activate “a novel once-daily, oral small-molecule GLP-1 receptor agonist” PMID 39495140 ↗ Nov 2024
Modality Small molecule “a novel once-daily, oral small-molecule GLP-1 receptor agonist” PMID 39495140 ↗ Nov 2024
Route Oral “ECC5004 was orally administered to NHPs for 9 months” PMID 39495140 ↗ Nov 2024
Target GLP1R “ECC5004 bound to the hGLP-1R (IC50 = 2.4 nM)” PMID 39495140 ↗ Nov 2024